Latest Headlines

Latest Headlines

Forest nabs Aptalis for $2.9B in its CEO's latest move toward a turnaround

Forest Laboratories, hungry for sales to replace its flailing antidepressant Lexapro, has sewn up a $2.9 billion deal for the specialty drugmaker Aptalis. It's the latest move in a wham-bam series of changes designed to get Forest back on a profitable track.

Thanks to Lexapro generics, Forest swings to loss on 32% drop in yearly sales

No one expected Forest Laboratories to post quarterly sales growth. How could it? The company's flagship drug, Lexapro, lost patent protection just as last year's fiscal fourth quarter drew to a close. So, this time around, Forest's sales were destined to drop.

Lundbeck launches alcohol dependence drug Selincro in heavy-drinking countries

After losing patent protection last year on the blockbuster antidepressant Lexapro, Danish drugmaker Lundbeck hopes to regain a least a bit of that vaporized revenue as it launches its anti-binge drinking drug Selincro in some European countries.

Sundance sees future for companion Dx to measure drug-related suicide risk

Sundance Diagnostics is pursuing a novel path for companion diagnostics development--blood tests that will gauge a patient's risk for suicide while taking certain antidepressant drugs. The new twist: The blood tests will be paired with prescription drugs already on the market.

Forest's Lexapro plague lingers with 41% hit to Q3 sales

Forest Laboratories is in dire need of a Bloody Mary for its still-severe Lexapro hangover. The U.S.-based drugmaker fell short of low expectations for the third quarter, thanks to a 41% drop in sales, largely because of generic competition for the blockbuster antidepressant. And the company ratcheted back predictions for its full-year results.

With FDA drug app in, Lundbeck gets much-needed good news

There was a glimmer of good news today for Lundbeck, which has been slashing its payroll and its earnings projections as it wrestles with the patent loss of blockbuster Lexapro.

Against tough odds, Lundbeck touts high-stakes R&D end game

With revenue numbers sliding now that Lexapro is getting battered by generic competition, Lundbeck has been refining its late-stage R&D game, and top execs want the world to know that it has a comeback strategy.

Lundbeck earnings undercut by Lexapro decline

Danish drugmaker Lundbeck, whose Lexapro sales have been depressed by generics, managed to maintain a flat operating profit in its third quarter as it works on a potential new blockbuster in hopes of better days to come.

Forest ties up with Brazil's Moksha8 in up to $125M alliance

Brazil's Moksha8 may be saying goodbye to Watson Pharmaceuticals ($WPI) as a minority owner. But it's saying hello to new business from the U.S. generics company--and a brand new partnership with Forest Laboratories. The latter not only wins Moksha8 up to $125 million in financing over the next two years; it also gives Forest the option to buy the Brazilian firm in 2014.

Lexapro goes skydiving, pulling Forest sales down 38%

We're wondering whether Forest Laboratories shareholders wish they could recast their proxy votes. The company's third-quarter sales tanked because of Lexapro's cut-rate generic competition, and it cut its outlook, both for revenue and earnings.